Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2003

View Archived Issues

Three series of MMP-13 inhibitors reported by AstraZeneca scientists

New ERbeta agonists and their use in hot flushes and depression

Novel antidiabetic agents in early development at Maxia

Novartis claims antiparkinsonian drugs targeting Nurr1 receptors

Antitumor polyketides prepared and tested at Novartis

Novartis patents new antitumor tyrosine kinase inhibitors

New series of PDE10A inhibitors with utility in cancer identified at Bayer

Novel phthalazine-based protein kinase inhibitors in Pharmacia pipeline

Janssen research team discovers new anti-HIV agents

Anti-PD-1 antibodies and their therapeutic use claimed by Ono

MediGene summarizes 2002 achievements

MediGene discontinues development of CVLP tumor vaccine

AEterna signs Neovastat marketing agreement for Korea

Development of BresaGen's E21R takes new direction

FDA extends review period for Tostrex NDA

ADVOCATE data reveal Advicor to be highly effective for lipid disorders

Resubmitted Plenaxis NDA accepted for review

Carlsson Research and Merck & Co. sign dopamine stabilizer program collaboration

Ceregene and Genentech sign gene license agreement

Three further companies express interest in Oxford GlycoSciences

KUR-1246 more effective than other beta2-agonists in rats with preterm labor

Sankyo discovers new inhibitor of Abeta-induced cytotoxicity

Varicella-zoster virus vaccine mutant impaired for latent infection offered by NIH

NIH licensing opportunity: materials and methods for inhibiting Wip1

Good safety reported for plasma DNA vaccine for HIV

Anti-PrP monoclonal antibodies show significant potential for prion diseases

Nonstyryl NMDA NR2B-selective antagonist with oral activity in rat pain model

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026